, /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it secured a judgment in its favor, in the amount of $80,416,101, on all claims it filed against defendants VGXI, Inc. ("VGXI") and GeneOne Life Science, Inc. ("GeneOne") in the case captioned INOVIO Pharmaceuticals, Inc. v. VGXI, Inc. and GeneOne Life Science, Inc., No. 2020-06554, in the Court of Common Pleas of Montgomery County, Pennsylvania. The Court awarded INOVIO $61,750,789 in compensatory damages and $18,665,312 in fees and costs. The Court also entered judgment against defendants on their counterclaims.
INOVIO filed the case on June 3, 2020, when defendants breached the parties' Supply Agreement by refusing to honor their technology transfer obligations to enable scalable manufacturing of DNA plasmids.
Defendants' financial condition will likely impair INOVIO's ability to collect some or all of the judgment. INOVIO intends to use every reasonable effort to recover the damages awarded by this judgment.
Cooley LLP and FBT Gibbons served as trial counsel for INOVIO.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools.
Forward-Looking Statements
This press release contains certain forward-looking statements relating to INOVIO's business, including statements regarding INOVIO's ability to collect on and realize the ultimate value from the judgment entered in INOVIO's favor against VGXI and GeneOne and the impact of defendants' financial condition on INOVIO's ability to enforce or collect any portion of the judgment. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including the risk that the judgment may be reduced, reversed, or otherwise modified on post-trial motions or appeal; the risk that defendants' financial condition will likely impair INOVIO's ability to collect some or all of the judgment, associated interest, fees and costs, notwithstanding INOVIO's intent to use every reasonable effort to recover the damages awarded; the time, expense, and uncertainty associated with collection and enforcement efforts; the adequacy of INOVIO's capital resources; the level of corporate expenditures; capital market conditions; and other factors set forth in INOVIO's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and other filings INOVIO makes from time to time with the Securities and Exchange Commission. There can be no assurance that INOVIO will collect any or all of the judgment, that the judgment will not be reduced, reversed, or otherwise modified, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and INOVIO undertakes no obligation to update or revise these statements, except as may be required by law.
Pyxis Oncology (NASDAQ:PYXS – Get Free Report) and Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk and valuation.
Earnings and Valuation This table compares Pyxis Oncology and Inovio Pharmaceuticals”s top-line revenue, earnings per share and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pyxis Oncology $13.86 million 14.02 -$79.62 million ($1.41) -1.65 Inovio Pharmaceuticals $60,000.00 2,102.47 -$84.95 million ($0.91) -1.34 Pyxis Oncology has higher revenue and earnings than Inovio Pharmaceuticals. Pyxis Oncology is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Analyst Ratings This is a summary of recent recommendations for Pyxis Oncology and Inovio Pharmaceuticals, as provided by MarketBeat.com.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pyxis Oncology 1 1 8 0 2.70 Inovio Pharmaceuticals 1 1 5 1 2.75 Pyxis Oncology currently has a consensus price target of $8.75, indicating a potential upside of 275.54%. Inovio Pharmaceuticals has a consensus price target of $3.17, indicating a potential upside of 159.56%. Given Pyxis Oncology’s higher possible upside, equities research analysts clearly believe Pyxis Oncology is more favorable than Inovio Pharmaceuticals.
Profitability This table compares Pyxis Oncology and Inovio Pharmaceuticals’ net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -215.23% -112.19% Inovio Pharmaceuticals N/A -669.94% -73.97% Institutional and Insider Ownership 39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 5.7% of Pyxis Oncology shares are owned by insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility & Risk Pyxis Oncology has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500.
About Pyxis Oncology (Get Free Report)
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
(Get Free Report)
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
Key Takeaways Rising P/E ratios often signal investor confidence, earnings strength and further upside potential. The screen identifies stocks with accelerating earnings growth and sustained price momentum. HTHT, INO, NMG and CCOI pair rising P/Es with strong earnings performance. Investors often opt for the stock-picking approach that involves stocks with a low price-to-earnings (P/E) ratio. This strategy is based on the notion that the lower the P/E ratio is, the higher the stock value. The reasoning behind this is straightforward — when a stock's current market price does not adequately reflect its higher earnings, it suggests potential for growth.
But there is more to this whole P/E story. Not only low P/E stocks, but also stocks with a rising P/E can fetch strong returns. In this regard, investors can bet on the likes of H World Group Limited Sponsored ADR (HTHT - Free Report) , Inovio Pharmaceuticals (INO - Free Report) , Nouveau Monde Graphite (NMG - Free Report) and Cogent Communications (CCOI - Free Report) .
Rising P/E: A Useful ToolThe concept is that as earnings rise, so should the price of the stock. As forecasts for expected earnings come in higher, strong demand for the stock should continue to push up its price. After all, astock's P/E gives an indication of how much investors are ready to shell out per dollar of earnings.
Suppose an investor wants to buy a stock with a P/E ratio of 30. This means that he is willing to shell out $30 for only $1 worth of earnings as he expects earnings of the company to rise at a faster pace in the future owing to strong fundamentals.
So, if the P/E of a stock is rising steadily, it means that investors are assured of its inherent strength and expect some strong positives out of it.
Also, studies have revealed that stocks have seen their P/E ratios jump over 100% from their breakout point in the cycle. So, if you can pick stocks early in their breakout cycle, you can end up seeing considerable gains.
The Winning StrategyIn order to shortlist stocks that are exhibiting an increasing P/E, we chose the following as our primary screening parameters.
EPS growth estimate for the current year is greater than or equal to last year’s actual growth
Percentage change in last year's EPS should be greater than or equal to zero
(These two criteria point to flat earnings or a growth trend over the years.)
Percentage change in price over four weeks greater than the percentage change in price over 12 weeks
Percentage change in price over 12 weeks greater than percentage change in price over 24 weeks
(These two criteria show that the price of the stock is increasing consistently over the said timeframes.)
Percentage price change for four weeks relative to the S&P 500 greater than the percentage price change for 12 weeks relative to the S&P 500
Percentage price change for 12 weeks relative to the S&P 500 greater than the percentage price change for 24 weeks relative to the S&P 500
(Here, the case for consistent price gains gets even stronger as it displays percentage price changes relative to the S&P 500.)
Percentage price change for 12 weeks is 20% higher than or equal to the percentage price change for 24 weeks, but it should not exceed 100%
(A 20% increase in the price of a stock from the breakout point gives cues of an impending uptrend. But a jump of over 100% indicates that there is limited scope for further upside and that the stock might be due for a reversal.)
In addition, we place a few other criteria that lead us to some likely outperformers.
Zacks Rank less than or equal to 2: Only companies with a Zacks Rank #1 (Strong Buy) or 2 (Buy) can get through.
Average 20-day Volume greater than or equal to 50,000: High trading volume implies that the stocks have adequate liquidity.
Just these few criteria narrowed down the universe from over 7,700 stocks to just 20.
Here are four out of the 20 stocks:
H World Group Limited Sponsored ADR: The Zacks Rank #2 company is involved in the hotel industry. You can see the complete list of today’s Zacks #1 Rank stocks here.
The average four-quarter earnings surprise of HTHT is 14.52%.
Inovio Pharmaceuticals: The Zacks Rank #2 company is engaged in the discovery, development and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases.
The average four-quarter earnings surprise of INO is 69.05%.
Nouveau Monde Graphite: The Zacks Rank #1 company is developing advanced carbon-neutral graphite-based material solutions for lithium-ion and fuel cell markets.
The average four-quarter earnings surprise of NMG is 106.17%.
Cogent Communications: The Zacks Rank #2 company is a Tier 1 Internet Service Provider that offers low-cost high-speed Internet access, private network services and colocation center services with ultra-low latency data transmission.
The average four-quarter earnings surprise of CCOI is 28.41%.
Palantir Bulls Face a Reality Check Before EarningsInovio Pharmaceuticals NASDAQ: INO said its biologics license application for INO-3107, an investigational DNA medicine for recurrent respiratory papillomatosis, or RRP, remains under U.S. Food and Drug Administration review, with a target action date of Oct. 30.
President and CEO Jacqueline Shea said the clinical-stage biotechnology company is in the late stages of the regulatory process for INO-3107 under the FDA’s Accelerated Approval Program. The company has completed its late-cycle review meeting and scheduled FDA inspections, she said. Inovio expects label negotiations with the agency to begin in September.
Get Inovio Pharmaceuticals alerts:
Let the Good Times Roll: 2 Stocks Showing No Signs of SlowingRRP is a rare disease caused by human papillomavirus types 6 or 11 that produces wart-like growths in the respiratory tract, particularly in the larynx and vocal cords. The condition can impair speaking, breathing and swallowing. Shea said RRP affects an estimated 14,000 people in the United States, with about 1.8 new adult cases per 100,000 people annually.
Repeated surgery remains the standard treatment because surgical procedures remove growths but do not address the underlying viral infection, Shea said. Some patients may require hundreds of surgeries over their lifetimes, and procedures can carry risks including irreversible vocal-cord damage.
Clinical Data and Regulatory Discussion 3 AI Stocks in Correction Mode: Can They Rebound?INO-3107 was designed to generate an antigen-specific T-cell response against HPV types 6 and 11. The company’s BLA is supported by its Phase I/II RRP-001 study and the RRP-002 follow-up study, which tracked patients after treatment without providing additional doses.
In RRP-001, enrolled patients had required at least two surgeries to manage their disease in the previous year. Patients received four doses of INO-3107 after entering the study following a clinically required surgery, and any surgery needed after the initial treatment date, including during the dosing period, was counted toward the study endpoint.
Shea said 72% of patients achieved a 50% to 100% reduction in surgeries during the first year after treatment compared with the prior year. That proportion rose to 86% in the second year. Meanwhile, 28% of patients required no surgeries in the first 12 months after treatment, increasing to 50% in the second 12 months. The extension study produced a median follow-up period of 2.8 years.
During a July informal clinical meeting with the FDA, Inovio presented its safety and efficacy data, its approach to RRP treatment and its rationale for accelerated approval eligibility, Shea said. The FDA did not discuss a preliminary comment in the file acceptance letter concerning accelerated approval eligibility, according to Shea, but indicated that feedback on the design of a confirmatory trial would be forthcoming.
The company said it believes INO-3107 could offer a differentiated profile because its clinical trial did not require surgeries during the dosing window to maintain minimal residual disease. Shea also said the DNA-based approach is not affected by pre-existing neutralizing antibodies and may avoid limitations associated with an immunosuppressive papilloma microenvironment.
Commercial Planning and Cash Runway As it approaches the FDA decision date, Inovio is preparing for a potential commercial launch. Shea said the company plans to use experienced field teams alongside a contract sales organization, a targeted marketing campaign and a patient-support hub. The company also intends to pursue access among payers and hospital systems and educate patients and caregivers about INO-3107’s potential profile.
Inovio said it has sufficient cash runway into late in the first quarter of next year, including through a potential INO-3107 launch.
Pipeline Partnerships Beyond INO-3107, Shea highlighted several partnered programs. In China, Inovio partner ApolloBio reported that its pivotal Phase III study of VGX-3100 for cervical dysplasia met its primary endpoint. ApolloBio plans to use the data to potentially seek approval in China and related territories. If approved, Inovio could receive regulatory and sales-based milestone payments as well as royalties, Shea said.
Inovio also recently partnered with Akeso to evaluate INO-5401 with Akeso’s bispecific checkpoint inhibitor in glioblastoma. The combination is planned for evaluation in the Dana-Farber Cancer Institute-sponsored INSIGhT trial. The companies aim to assess whether the regimen can improve survival and delay disease progression in patients with the brain cancer.
Shea additionally discussed Inovio’s earlier-stage dMAb and dProt platforms, which are intended to produce antibodies or therapeutic proteins directly within the body. In a Phase I trial involving SARS-CoV-2 antibodies, the company said it produced two monoclonal antibodies at potentially therapeutic levels for up to 96 weeks, with stable blood levels, no observed anti-drug antibodies and injection-site reactions as the most common side effect.
The company has also presented preclinical hemophilia A data and disclosed work in Fabry disease and hypophosphatasia. Inovio is seeking partners to advance those rare-disease programs and other platform opportunities.
About Inovio Pharmaceuticals (NASDAQ:INO)Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio's business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.
Central to Inovio's platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Inovio Pharmaceuticals Right Now?Before you consider Inovio Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inovio Pharmaceuticals wasn't on the list.
While Inovio Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Palantir Bulls Face a Reality Check Before EarningsInovio Pharmaceuticals NASDAQ: INO is approaching an October 30 PDUFA date for INO-3107, its lead DNA medicine candidate for recurrent respiratory papillomatosis, or RRP, President and CEO Jacky Shea said during a Cantor Fitzgerald fireside chat.
Shea described Inovio as a clinical-stage company developing DNA medicines for HPV-related diseases, cancer and infectious diseases. The company’s platform uses plasmid DNA delivered through its proprietary CELLECTRA device, which applies brief electrical pulses to help the DNA enter skin or muscle cells. Once inside cells, the plasmids are transcribed into mRNA and translated into proteins intended to produce sustained protein levels or generate immune responses.
Get Inovio Pharmaceuticals alerts:
Let the Good Times Roll: 2 Stocks Showing No Signs of SlowingAccording to Shea, the platform is particularly suited to producing antigen-specific T-cell responses, which the company sees as important in cancer and virally mediated diseases. In the United States, CELLECTRA is regulated as part of a combination product rather than through a separate approval process. The device already has CE marking in the European Union, she said.
RRP Program Targets Repeat Surgery Burden RRP is caused primarily by HPV types 6 and 11 and can lead to wart-like papilloma growths around the vocal cords, Shea said. The condition can make speaking, swallowing and breathing difficult, while in some cases disease can spread through the respiratory tract and become malignant.
3 AI Stocks in Correction Mode: Can They Rebound?Current care generally relies on surgical removal of papillomas, either through laser procedures or scalpels. However, surgery does not eliminate the underlying virus, Shea said, meaning papillomas can return and patients can face repeat procedures. Those procedures can also cause permanent scarring or damage to vocal cords and respiratory tissues.
Inovio’s Phase I/II study of INO-3107 enrolled 32 patients with confirmed HPV 6- or HPV 11-associated RRP who had undergone two to eight surgeries in the preceding year. Patients received four doses over nine weeks after a clinically required surgery.
In the first year after treatment, 72% of patients experienced a 50% to 100% reduction in surgeries compared with the prior year, according to Shea. That figure increased to 86% in the second year. Twenty-eight percent of patients required no surgeries in year one, rising to 50% in year two. Shea said the trial showed mainly grade 1 and grade 2 adverse events, with few systemic events. She also said patients have reported mild-to-moderate injection-site discomfort from the CELLECTRA administration process that generally resolves within five to 10 minutes.
FDA Review and Potential Confirmatory Trial INO-3107’s biologics license application was submitted under the accelerated approval pathway. Shea said the FDA’s file acceptance letter included a preliminary conclusion that the application might not be eligible for review under that pathway.
Because an RRP product had previously received full approval, Inovio must demonstrate continuing unmet need and meaningful therapeutic benefit over available treatment to support accelerated approval, Shea said. The company subsequently submitted an assessment aid containing its clinical safety and efficacy data along with additional FDA-requested analyses.
Inovio held an informal clinical meeting with the FDA in July. Shea said company representatives were joined by patient advocacy organizations and a physician treating RRP patients, who discussed the continued unmet need and potential clinical benefit of INO-3107. The FDA did not comment on the review pathway at that time because the review was at a late stage, she said.
The company has completed pre-licensure inspections, receiving one observation that it believes has been resolved. Shea said Inovio expected to enter labeling discussions in September, while noting that the company would also need to confirm the design of any accelerated-approval confirmatory trial with the FDA.
Inovio had previously proposed a placebo-controlled study of about 100 patients, randomized two-to-one between active treatment and placebo. Shea said the study could include year-one and year-two readouts to confirm clinical benefit, although the FDA could request additional patients or endpoints.
Commercial Preparation and Pipeline Plans Shea said Inovio has made key commercial preparations for a potential launch, including partnerships for specialty distribution, specialty pharmacy, patient support and third-party logistics. The company is also working with Syneos Health for contract sales and medical science liaison deployment.
RRP treatment is concentrated among an estimated 300 to 400 laryngologists at roughly 100 U.S. treatment centers, Shea said. Inovio estimates at least 14,000 potential RRP patients based on claims-database work, though Shea said the company believes the number could be higher.
Beyond INO-3107, Inovio’s clinical pipeline includes INO-3112 for HPV 16- and HPV 18-positive head and neck cancer, partnered with Coherus, and a glioblastoma program partnered with Akeso. The company also has earlier-stage protein-replacement work in hemophilia A, Fabry disease and hypophosphatasia.
At the end of the second quarter, Inovio had $36.7 million in cash. Shea said a subsequent offering generated $18.3 million in net proceeds, extending the company’s cash runway into the end of the first quarter of 2027 and through a potential INO-3107 launch if approved.
About Inovio Pharmaceuticals (NASDAQ:INO)Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio's business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.
Central to Inovio's platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Inovio Pharmaceuticals Right Now?Before you consider Inovio Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inovio Pharmaceuticals wasn't on the list.
While Inovio Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Inovio Pharmaceuticals, Inc. (INO) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 9, 2026 3:20 PM EDT
Company Participants
Jacqueline Shea - CEO, President & Director
Conference Call Participants
Eric Schmidt - Cantor Fitzgerald & Co., Research Division
Alexa Deemer - Cantor Fitzgerald & Co., Research Division
Presentation
Eric Schmidt
Cantor Fitzgerald & Co., Research Division
So Inovio represented by Jacqui Shea, the company's President and CEO. My name is Eric Schmidt. I'm one of the biotechnology analysts at Cantor Fitzgerald, and I'm sharing this fireside chat with my colleague, Alexa Deemer. So Jacqui, thank you for coming. Maybe just high level, I know you've got an important FDA action date coming around the corner, which we're going to get into. But for those less familiar with Inovio, what are the 2-minute highlights?
Jacqueline Shea
CEO, President & Director
Yes. Well, first of all, thanks very much for the invitation. It's nice to be here today. So Inovio is a clinical-stage company. We're focused on developing DNA medicines to help treat and prevent HPV-related diseases, cancer and infectious diseases. As Eric mentioned, we've got a very exciting PDUFA date coming up in a few weeks' time, on the 30th of October, for our lead program, which is INO-3107 for the treatment of recurrent respiratory papillomatosis or RRP. And following on behind that also based on our DNA medicines platform, we have a deep clinical pipeline of other candidates.
Question-and-Answer Session
Eric Schmidt
Cantor Fitzgerald & Co., Research Division
So tell us a little bit more about your DNA medicines platform, what that means, what that entails?
Jacqueline Shea
CEO, President & Director
Yes. So DNA medicines have been around for quite a while. And what makes Inovio different is really our delivery system. So we start off by identifying target proteins that we want
, /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following investor conferences:
Cantor Global Healthcare Conference (New York)
Date: Wednesday, September 9
Fireside Chat: 3:20 PM ET
Webcast: https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=99315971&checkCompany=1&checkEmail=1&checkName=1
H.C. Wainwright 28th Annual Global Investment Conference (New York)
Presentation Available: Beginning Friday, September 11, 7:00 AM ET
Format: Virtual
Link: https://journey.ct.events/view/eb47953c-3213-432d-92ca-13beb55c97ae
Replays of the investor presentations will be available for 90 days at the links above. During these conferences members of INOVIO's management team will also be conducting one-on-one meetings with investors.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Palantir Bulls Face a Reality Check Before EarningsInovio Pharmaceuticals NASDAQ: INO said the U.S. Food and Drug Administration has completed several key steps in its review of the company’s biologics license application for INO-3107, an investigational treatment for recurrent respiratory papillomatosis, or RRP, while the company continues preparations for a potential commercial launch.
The FDA’s target action date for the application remains Oct. 30, 2026. Chief Executive Officer Dr. Jacqueline Shea said the agency has completed its late-cycle review meeting and all scheduled pre-licensure inspections. Inovio also held a previously requested informal clinical meeting with the FDA in July to present its safety, efficacy and product-differentiation data.
Get Inovio Pharmaceuticals alerts:
Regulatory Review Nears Final Stages Let the Good Times Roll: 2 Stocks Showing No Signs of SlowingChief Medical Officer Dr. Mike Sumner said the completed inspections covered clinical operations, drug manufacturing, in-house drug testing and the company’s delivery-device facility. He said inspectors reported one observation, which Inovio believes it has addressed and is responding to with the FDA.
Sumner said the FDA did not provide a preliminary conclusion during the informal meeting on whether INO-3107 qualifies for accelerated approval, an issue identified in the agency’s December 2025 file-acceptance letter. The agency indicated that its review remains ongoing and that feedback on Inovio’s proposed confirmatory trial design is forthcoming.
3 AI Stocks in Correction Mode: Can They Rebound?Inovio believes INO-3107 meets accelerated-approval criteria because it could offer meaningful therapeutic benefit relative to existing treatments and address a continuing unmet need in RRP. The company cited phase I/II data in which it said most patients experienced a 50% to 100% reduction in surgeries during the first year, with continued improvement in the second year.
Management also highlighted what it views as product advantages over Pepzimos, including that INO-3107 does not require patients to undergo scoping and surgery during its dosing window to maintain minimal residual disease. Sumner said Inovio expects to begin label negotiations in September and, if the product is approved, expects seven years of orphan-drug market exclusivity based on its delivery method and mechanism of action.
Commercial Infrastructure Takes Shape Chief Commercial Officer Steve Egge said Inovio has moved into the implementation phase of launch planning. The company has selected Syneos Health as its contract sales organization for a potential U.S. commercialization effort and plans targeted marketing efforts and a patient-support hub.
Egge said early uptake of Pepzimos, with approximately 200 patients reportedly treated, validates demand for alternatives to surgery. He characterized that figure as low-single-digit penetration of the prevalent RRP patient population, leaving most patients open to new treatment options.
Inovio said INO-3107’s potential commercial differentiation includes the absence of specialized ultra-cold-chain handling requirements, which management said could provide greater flexibility across care settings. The company is also initiating its medical science liaison team to begin scientific engagement with potential customers.
Pipeline Partnerships and DPROT Development Beyond INO-3107, Shea highlighted positive top-line phase III results announced by ApolloBio, Inovio’s Greater China partner for VGX-3100 in cervical dysplasia. According to Inovio, the study met its predefined primary efficacy endpoint of CIN 2 or CIN 3 lesion regression and HPV-16 and HPV-18 viral clearance, while demonstrating a favorable safety and tolerability profile.
ApolloBio plans to use the results to support a future regulatory filing for VGX-3100 in China. Inovio said the results support the potential for DNA medicines to address HPV-related diseases while reducing or eliminating the need for surgical intervention.
The company also presented preclinical research involving its DNA-encoded protein, or DPROT, platform targeting factor VIII production for hemophilia A at scientific conferences during the quarter. Inovio added Fabry disease and hypophosphatasia as rare-disease targets for the platform and said it is in discussions with potential partners to advance DPROT candidates.
Second-Quarter Financial Results and Cash Runway Chief Financial Officer Peter Kies said Inovio ended the second quarter with $36.7 million in cash, cash equivalents and short-term investments, compared with $58.5 million at Dec. 31, 2025. In late July, the company completed an underwritten public offering that generated approximately $18.3 million in net proceeds.
Second-quarter operating expenses declined 19% year over year to $18.6 million from $23.1 million. Operating expenses for the first six months of 2026 decreased 16% from the prior-year period. Net loss was $6 million, or $0.07 per share, compared with a net loss of $23.5 million, or $0.61 per share, a year earlier. The lower net loss included a $13.9 million non-cash gain from the fair-value adjustment of warrant liabilities. Inovio estimated operational net cash burn of approximately $18 million for the third quarter and said its available resources, including the July offering proceeds, are expected to fund operations into late first quarter of 2027 and through a potential INO-3107 launch. Kies said that outlook includes expected pre-launch inventory-building and marketing costs during the fourth quarter and first quarter.
About Inovio Pharmaceuticals (NASDAQ:INO)Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio's business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.
Central to Inovio's platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Should You Invest $1,000 in Inovio Pharmaceuticals Right Now?Before you consider Inovio Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inovio Pharmaceuticals wasn't on the list.
While Inovio Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP) advancing with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026 Commercial preparations advancing in anticipation of potential product launch for INO-3107 Positive topline results reported from Phase 3 trial for VGX-3100 for the treatment of cervical dysplasia patients by ApolloBio, INOVIO's partner in China Presented promising data from next-generation DNA-Encoded Monoclonal Antibody (DMAb™) and DNA-Encoded Protein (DPROT) programs at several scientific conferences Current cash, cash equivalents, and short-term investments anticipated to fund operations into late first quarter 2027, through a potential launch of INO-3107, if approved , /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter ended June 30, 2026 and provided an update on recent company developments.
"As the FDA's review of our BLA for INO-3107 continues to advance, we are pleased to have held the informal clinical meeting with the FDA, where we presented the totality of data supporting INO-3107's safety and efficacy and highly differentiated approach in treating RRP, and our rationale for accelerated approval eligibility," said Dr. Jacqueline Shea, INOVIO's President and Chief Executive Officer. "We are confident in INO-3107's potential to become the preferred product among patients, healthcare providers and payers, if approved, and are committed to ensuring that all patients have access to therapeutic options that work for them in reducing the need for surgery to control their disease. We look forward to the final stages of the review process and further advancing our commercial preparations."
Operational Highlights
INO-3107 – Recurrent Respiratory Papillomatosis (RRP)
The FDA's review of the BLA for INO-3107 continues to advance under the Agency's accelerated approval program toward a PDUFA target action date of October 30, 2026. Regulatory progress includes completion of the late-cycle review meeting and all scheduled pre-licensure inspections. An informal clinical meeting was conducted, where INOVIO presented the totality of data supporting INO-3107's safety and efficacy and highly differentiated approach in treating RRP, along with the company's rationale for accelerated approval eligibility. During the informal meeting, the FDA did not discuss its preliminary comment in the file acceptance letter regarding accelerated approval eligibility. In addition, the FDA stated that feedback on the confirmatory trial design would be forthcoming. INOVIO continues to believe that INO-3107 fulfills the criteria for accelerated approval by meeting an unmet clinical need and providing a meaningful therapeutic benefit over existing treatments.
In anticipation of a potential approval in 2026, INOVIO is preparing its commercial launch activities. Recently, INOVIO engaged Syneos Health to recruit and deploy Medical Science Liaisons (MSLs), and Syneos Health is also serving as the company's contract sales organization to support commercialization in the U.S. INOVIO has also engaged or identified key commercial partners, including a third-party logistics provider, Agency of Record, specialty distributor, specialty pharmacy, and patient hub.
The FDA previously granted INO-3107 both Orphan Drug and Breakthrough Therapy designations.
VGX-3100 – Cervical Dysplasia (High-grade Squamous Intraepithelial Lesions)
In May 2026, INOVIO's partner for VGX-3100 in Greater China, ApolloBio, announced positive topline results from its pivotal Phase 3 trial of VGX-3100 as a potential treatment for cervical dysplasia. The trial successfully met its predefined primary efficacy endpoint and demonstrated an overall favorable safety and tolerability profile. ApolloBio plans to use the results from the study to support a future filing for regulatory approval of VGX-3100 in China. VGX-3100 is INOVIO's investigational DNA immunotherapy developed for diseases associated with high-risk human papillomavirus (HPV) types 16 and 18.
Next-Generation DNA Medicine Candidates
INOVIO presented promising data from our next-generation DNA-Encoded Monoclonal Antibody (DMAb™) and DNA-Encoded Protein (DPROT) programs at the American Society of Gene and Cell Therapy Annual Meeting in May 2026 and the World Orphan Drug Congress in June 2026, highlighting positive preclinical data on Factor VIII production for Hemophilia A. INOVIO is continuing discussions with potential partners to accelerate development of this promising platform with a focus on developing additional DPROT indications in the rare disease space, including Fabry Disease and Hypophosphatasia (HPP).
General Corporate
INOVIO remains focused on financial discipline, directing resources to advance the INO-3107 program toward a potential 2026 approval and preparing for commercialization. The company strengthened its balance sheet with an underwritten public equity offering in July 2026. Net proceeds from the offering, after deducting underwriting discounts, commissions and offering expenses, were approximately $18.3 million.
Second Quarter 2026 Financial Results
Research and Development (R&D) Expenses: R&D expenses for the three months ended June 30, 2026 decreased to $10.8 million from $14.5 million for the same period in 2025. The decrease was primarily the result of lower employee and consultant compensation, including stock-based compensation, lower engineering outside services related to our device development, and lower inventory expenses, among other variances. General and Administrative (G&A) Expenses: G&A expenses decreased to $7.8 million for the three months ended June 30, 2026 from $8.6 million for the same period in 2025. Total Operating Expenses: Total operating expenses decreased to $18.6 million for the three months ended June 30, 2026 from $23.1 million for the same period in 2025. Net Loss: INOVIO's net loss for the three months ended June 30, 2026 was $6.0 million, or $0.07 per basic and diluted share, compared to a net loss of $23.5 million, or $0.61 per basic and diluted share, for the three months ended June 30, 2025. The decrease in net loss was primarily driven by a $13.9 million non-cash gain on fair value adjustment related to our warrant liabilities for the three months ended June 30, 2026. As the fair value of the warrants fluctuates with our share price and other market inputs, this adjustment can result in significant variability in our reported net loss. Cash, Cash Equivalents and Short-term Investments: As of June 30, 2026, cash, cash equivalents and short-term investments were $36.7 million (excluding net proceeds from the July 2026 offering of approximately $18.3 million), compared to $58.5 million as of December 31, 2025. Cash Guidance
INOVIO estimates that current cash, cash equivalents and short-term investments balances will support operations into late first quarter 2027, through a potential launch of INO-3107, if approved. This projection includes the net proceeds of approximately $18.3 million from the public offering in July 2026, as well as an operational net cash burn estimate of approximately $18 million for the third quarter of 2026. These cash runway projections do not include any further capital-raising activities that INOVIO may undertake.
Conference Call / Webcast Information
INOVIO's management will host a live conference call and webcast with slides at 4:30 p.m. ET today to discuss INOVIO's financial results and provide a general business update. The live webcast and replay may be accessed by visiting INOVIO's website at http://ir.inovio.com/events-and-presentations/default.aspx.
About INOVIO's DNA Medicines Platform
INOVIO's DNA medicines platform has two innovative components: precisely designed DNA plasmids, delivered by INOVIO's proprietary investigational medical device, CELLECTRA. INOVIO uses proprietary technology to design its DNA plasmids, which are small circular DNA molecules that work like software the body's cells can download to produce specific proteins to target and fight disease. INOVIO's proprietary CELLECTRA delivery devices are designed to optimally deliver its DNA medicines to the body's cells without requiring chemical adjuvants or lipid nanoparticles and without the risk of the anti-vector response historically seen with viral vector platforms.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing innovative DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Forward-Looking Statements
This press release contains certain forward-looking statements relating to our business, including the timing and success of preclinical studies and clinical trials; the ability to obtain and maintain regulatory approval of our product candidates; the FDA's continued review of our BLA for INO-3107 toward a PDUFA target action date of October 30, 2026; the outcome of our meeting with the FDA to discuss eligibility for the accelerated approval program, including feedback on our proposed confirmatory trial design; the potential benefits of INO-3107 and our other potential product candidates, including our belief that INO-3107 has a positively differentiated product profile and the potential to become the preferred product by patients and their physicians, if approved; the scope, progress and expansion of developing and commercializing our product candidates, including the anticipated commercial launch of INO-3107, if approved; our anticipated growth strategies; our ability to establish and maintain development partnerships; our estimated operational net cash burn of approximately $18 million for the third quarter of 2026; and the expected sufficiency of our cash resources through a potential launch of INO-3107, if approved, and into late first quarter 2027. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials, product development programs and commercialization activities and outcomes, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured, or commercialized, that the results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its second quarter 2026 financial results will be released after the market close on August 12th, 2026. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a general business update.
The live webcast will be available online at http://ir.inovio.com/events-and-presentations/default.aspx. This is a listen-only event but will include a live Q&A with analysts. The webcast will be archived and available for replay for 90 days following the event.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing innovative DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com
, /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 21,052,632 shares of its common stock and accompanying warrants to purchase up to 42,105,264 shares of its common stock (or pre-funded warrants in lieu thereof) with an exercise price of $1.10 per share of common stock, at a combined public offering price of $0.95 per share of common stock and accompanying warrant to purchase two shares of common stock. INOVIO also granted the underwriter an option for a period of 30 days to purchase up to 3,157,894 additional shares of the Company's common stock and/or warrants to purchase up to 6,315,788 additional shares of its common stock (or pre-funded warrants in lieu thereof) at the public offering price, less the underwriting discounts and commissions. All of the securities in the offering are being sold by INOVIO. The offering is expected to close on or about July 31, 2026, subject to the satisfaction of customary closing conditions.
The gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by INOVIO, and excluding any exercise of the underwriter's option to purchase additional securities and assuming no exercise of the accompanying warrants, are expected to be approximately $20.0 million.
Piper Sandler is acting as sole manager for the offering.
A shelf registration statement relating to the shares of common stock and accompanying warrants offered in the offering described above was filed with the Securities and Exchange Commission ("SEC") on July 2, 2026 and declared effective by the SEC on July 10, 2026. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering were filed with the SEC and are available on the SEC's website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting: Piper Sandler & Co., 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by e-mail at [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools.
Forward-Looking Statements
This release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include, but are not limited to, statements regarding the public offering of INOVIO's securities, including the timing of the closing of the offering, as well as the anticipated proceeds of the offering. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public offering. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in INOVIO's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and in other filings that INOVIO makes with the SEC from time to time. There can be no assurance that any of the forward-looking information provided herein will be proven accurate. These forward-looking statements speak only as of the date hereof and INOVIO undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.
, /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof), in an underwritten public offering. INOVIO intends to grant the underwriter a 30-day option to purchase additional shares of its common stock and/or accompanying warrants in an amount up to 15% of the shares of its common stock and/or accompanying warrants offered in the public offering under the same terms and conditions. All of the securities in the proposed offering will be sold by INOVIO. The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
Piper Sandler is acting as sole manager for the offering.
A shelf registration statement relating to the shares of common stock and accompanying warrants offered in the offering described above was filed with the Securities and Exchange Commission ("SEC") on July 2, 2026 and declared effective by the SEC on July 10, 2026. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting: Piper Sandler & Co., 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by e-mail at [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools.
Forward-Looking Statements
This release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include, but are not limited to, statements regarding INOVIO's anticipated public offering, including the completion of the public offering on the anticipated terms, if at all, and INOVIO's plans to grant the underwriter a 30-day option to purchase additional shares and/or warrants. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public offering. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in INOVIO's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and in other filings that INOVIO makes with the SEC from time to time. There can be no assurance that any of the forward-looking information provided herein will be proven accurate. These forward-looking statements speak only as of the date hereof and INOVIO undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Inovio (INO) To Contact Him Directly To Discuss Their Options
If you purchased or acquired Inovio securities between October 10, 2023 and December 26, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) --
What’s Happening:
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ:INO) in the United States District Court for the Eastern District of Pennsylvania on behalf of all persons and entities who purchased or otherwise acquired Inovio securities between October 10, 2023 and December 26, 2025, both dates inclusive (the “Class Period”). Investors have until April 7, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Allegation Details:
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) manufacturing for Inovio’s CELLECTRA device was deficient; (2) accordingly, Inovio was unlikely to submit the INO-3107 Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA’s eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107’s overall regulatory and commercial prospects were overstated; and (5) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. On December 29, 2025, the U.S. Food and Drug Administration ("FDA") announced it had accepted Inovio's Biologics License Application ("BLA") for INO-3107, a treatment for recurrent respiratory papillomatosis, on a standard review timeline. Inovio filed its BLA under the accelerated approval pathway, but the FDA stated that the Company did not submit adequate information to justify eligibility for accelerated approval. Inovio also announced it does not currently plan to seek approval under the standard review timeline, and will request a meeting with the FDA to discuss how it may still pursue accelerated approval. On this news, Inovio's stock price fell $0.56 per share, or 24.45%, to close at $1.73 per share on December 29, 2025. Next Steps:
If you purchased or otherwise acquired Inovio shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.
, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Inovio Pharmaceuticals, Inc. (NASDAQ: INO).
Shareholders who purchased shares of INO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: October 10, 2023 to December 26, 2025
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) manufacturing for Inovio's CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit it's lead product candidate, INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's overall regulatory and commercial prospects were overstated; and (v) as a result, defendants' public statements were materially false and misleading at all relevant times.
DEADLINE: April 7, 2026 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/inovio-pharmaceuticals-inc-loss-submission-form-2/?id=185253&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of INO during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 7, 2026. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Inovio to Contact Him Directly to Discuss Their Options
If you purchased or acquired securities in Inovio between October 10, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO) and reminds investors of the April 7, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) manufacturing for Inovio's CELLECTRA device was deficient; (2) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory and commercial prospects were overstated; and (5) as a result, Defendants' public statements were materially false and misleading at all relevant times.
On December 29, 2025, the U.S. Food and Drug Administration (“FDA”) announced it had accepted Inovio’s Biologics License Application (“BLA”) for INO-3107, a treatment for recurrent respiratory papillomatosis, on a standard review timeline. Inovio filed its BLA under the accelerated approval pathway, but the FDA stated that the Company did not submit adequate information to justify eligibility for accelerated approval. Inovio also announced it does not currently plan to seek approval under the standard review timeline, and will request a meeting with the FDA to discuss how it may still pursue accelerated approval.
On this news, Inovio’s stock price fell $0.56 per share, or 24.45%, to close at $1.73 per share on December 29, 2025.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Inovio’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Inovio class action, go to www.faruqilaw.com/INO or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the “Class Period”). Inovio is a biotechnology company.
For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.
The Allegations: Rosen Law Firm is Investigating the Allegations that Inovio Pharmaceuticals, Inc. (NASDAQ: INO) Misled Investors Regarding its Business Operations.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) manufacturing for Inovio’s CELLECTRA device was deficient; (2) accordingly, Inovio was unlikely to submit the INO-3107 Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA’s eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107’s overall regulatory and commercial prospects were overstated; and (5) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
What Now: You may be eligible to participate in the class action against Inovio Pharmaceuticals, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by April 7, 2026. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline.
So what: If you purchased Inovio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next: To join the Inovio class action, go to https://rosenlegal.com/submit-form/?case_id=52847 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Details of the case: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) manufacturing for Inovio's CELLECTRA device was deficient; (2) accordingly, Inovio was unlikely to submit the INO-3107 Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory and commercial prospects were overstated; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Inovio class action, go to https://rosenlegal.com/submit-form/?case_id=52847 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO) and certain officers. The class action, filed in the United States District Court for the Eastern District of Pennsylvania, and docketed under 26-cv-00803, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Inovio securities between October 10, 2023 and December 26, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
If you are an investor who purchased or otherwise acquired Inovio securities during the Class Period, you have until April 7, 2026, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
[Click here for information about joining the class action]
Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papilloma virus (“HPV”). The Company’s DNA medicines are comprised of two components: (i) DNA plasmids, which are small circular DNA molecules that purportedly work like software that the body’s cells can download to produce specific proteins to target and fight disease; and (ii) its proprietary investigational medical device, “CELLECTRA,” which it uses to help its DNA medicines enter the body’s cells for purported optimal effect.
Inovio’s lead product candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (“RRP”), a life-long, rare disease of the respiratory tract caused by HPV infection. At all relevant times, Defendants touted the prospects of the U.S. Food and Drug Administration (“FDA”) granting accelerated approval and/or priority review for the Biologics License Application (“BLA”) of INO-3107 for the treatment of RRP (the “INO-3107 BLA”). Defendants also touted their ability to complete rolling submission of the INO-3107 BLA by the second half of 2024. In so doing, Defendants consistently and repeatedly indicated to investors that Inovio was rapidly approaching its transition into a commercial-stage company—one with a lead product asset that, once approved, would fill an unmet medical need and significantly improve the safety or effectiveness of current RRP treatments. The commercial implications of this prospect, which Defendants consistently highlighted throughout the Class Period, were of the upmost importance to investors and analysts, and formed a core part of the Company’s overall investment thesis.
Simultaneously, while disseminating these positive statements to the market, throughout the Class Period Defendants conducted numerous offerings of Inovio’s securities, reaping profits of tens of millions of dollars per offering.
Throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) manufacturing for Inovio’s CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA’s eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107’s overall regulatory and commercial prospects were overstated; and (v) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
The truth began to emerge on August 8, 2024, when, during post-market hours, Inovio issued a press release reporting its financial results and recent business highlights for the second quarter of 2024. Therein, Defendants revealed that Inovio expected to submit the INO-3107 BLA to the FDA in mid-2025—representing an approximate full-year delay from Defendants’ initially projected mid-2024 submission timeline—because of “a manufacturing issue” with a component of the CELLECTRA device.
On this news, Inovio’s stock price fell $0.27 per share, or 3.1%, to close at $8.44 per share on August 9, 2024.
Then, on December 29, 2025, during pre-market hours, Inovio issued a press release announcing that the FDA had accepted the INO-3107 BLA on a standard rather than accelerated review timeline. Defendants advised that the FDA had indicated that the Company did not submit adequate information to justify eligibility for accelerated approval. Defendants further advised that Inovio does not plan to seek approval under the standard review timeline and would request a meeting with the FDA to discuss how it may still pursue accelerated approval.
On this news, Inovio’s stock price fell $0.56 per share, or 24.45%, to close at $1.73 per share on December 29, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its first quarter 2026 financial results will be released after the market close on May 13th, 2026. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a general business update.
The live webcast will be available online at http://ir.inovio.com/events-and-presentations/default.aspx. This is a listen-only event but will include a live Q&A with analysts. The webcast will be archived and available for replay for 90 days following the event.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing innovative DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com
, /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following scientific conferences:
American Society of Gene and Cell Therapy Annual Meeting (Boston)
Poster Presentation: Bleeding phenotype correction in hemophilia A mice following in vivo Factor VIII gene transfer by electroporation in skeletal muscle cells
Date: Tuesday, May 12
Time: 5 - 6:30 PM ET
American Society of Clinical Oncology Annual Meeting (Chicago)
Poster Presentation: B cell responses in Recurrent Respiratory Papillomatosis patients treated with DNA immunotherapy INO-3107
Date: Saturday, May 30
Time: 1:30 - 4:30 PM CDT
Available abstracts will be shared on INOVIO's website following presentations.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Biologics License Application (BLA) for INO-3107 actively being reviewed under the accelerated approval program by the U.S. Food and Drug Administration (FDA) with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026 Commercial readiness plans continue to advance in anticipation of a potential commercial launch for INO-3107 as a treatment for adults with Recurrent Respiratory Papillomatosis (RRP) Clinical trial collaboration and supply agreement announced with Akeso Inc. to evaluate INO-5412 in combination with cadonilimab for the potential treatment of glioblastoma (GBM) in a Dana-Farber Cancer Institute-sponsored trial Current cash, cash equivalents, and short-term investments anticipated to fund operations into first quarter 2027, beyond the target PDUFA date , /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter ended March 31, 2026 and provided an update on recent company developments.
"We remain focused on advancing INO-3107 toward its target PDUFA date to ensure that every RRP patient has access to therapeutic options that work for them to reduce the need for surgery. We believe there remains a critical unmet need among patients diagnosed with this rare and devastating disease, and that INO-3107 has the potential to become the preferred product by patients and their physicians, if approved, based on clinical results, tolerability data and the simplicity of its patient-centric treatment regimen that does not require additional surgeries during the dosing window," said Dr. Jacqueline Shea, INOVIO's President and Chief Executive Officer. "While the BLA for INO-3107 is under active review, we continue to advance our commercial readiness plans in anticipation of a 2026 approval, as well as leverage the power of partnerships to advance other promising candidates in our pipeline."
Operational Highlights
INO-3107 – Recurrent Respiratory Papillomatosis (RRP)
INO-3107 is INOVIO's lead product candidate. It has been developed as a potential treatment for RRP, a rare and debilitating disease of the respiratory tract caused by infection with HPV-6 and/or HPV-11. In December 2025, the FDA accepted for review the company's BLA for INO-3107 under the accelerated approval program and set a target PDUFA date for October 30, 2026. Since then, the BLA has been under active review by the FDA, including the recent completion of the mid-cycle review meeting. INOVIO is focused on advancing INO-3107 through the regulatory process and working with the FDA as they complete their review of the BLA, including addressing the potential review issue they noted in their file acceptance letter regarding eligibility for review under the accelerated approval program. INOVIO continues to strongly believe that INO-3107 fulfills the criteria for accelerated approval by meeting a significant unmet need and providing a meaningful therapeutic benefit over existing treatments. As a part of communications about the mid-cycle review, the FDA has reiterated their intention to schedule the previously agreed to informal meeting to discuss their preliminary commentary on eligibility for review under the accelerated approval program.
INOVIO continues to engage with the RRP community, including presenting data from our Phase 1/2 trial of INO-3107 at the Combined Otolaryngology Spring Meeting (COSM), the premier educational and technology forum for the specialists who treat RRP. INOVIO will also be presenting at the upcoming American Society of Clinical Oncology (ASCO) Annual Conference.
In anticipation of a potential approval in 2026, INOVIO continues to advance commercial readiness plans, including incorporating key learnings from the launch of a competitor's recently approved RRP product. INOVIO believes INO-3107 has a positively differentiated product profile. INOVIO plans to commercialize INO-3107 itself in the U.S., with the support of a contract sales organization, and has engaged or identified key commercial partners, including a third-party logistics provider, Agency of Record, specialty distributor, specialty pharmacy, and patient HUB.
INO-5412
In March 2026, INOVIO announced a clinical trial collaboration and supply agreement with Akeso Inc. to evaluate INO-5412 (INO-5401 plus INO-9012 in a single vial) in combination with cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, for the potential treatment of glioblastoma (GBM). The combination therapy will be studied as a part of the INdividualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT), a Phase 2 adaptive platform trial sponsored by the Dana-Farber Cancer Institute and conducted by Mass General Brigham Cancer Care Inc. This novel combination builds on INOVIO's previous promising research in GBM and could potentially benefit patients by providing additional checkpoint inhibition through CTLA-4 binding.
Next-Generation DNA Medicine Candidates
INOVIO presented promising data from our next-generation DNA-Encoded Monoclonal Antibody (DMAb™) and DNA-Encoded Protein (DPROT) programs at several recent scientific conferences. Based on positive preclinical data on Factor VIII production for Hemophilia A, INOVIO is developing additional DPROT indications in the rare disease space, including Fabry disease and Hypophosphatasia (HPP), and is in discussions with potential partners to accelerate development of this promising platform.
General Corporate
INOVIO remains focused on financial discipline, directing resources to advance the INO-3107 program toward a potential 2026 approval and preparing for commercialization. The company strengthened its balance sheet with an underwritten public equity offering in April 2026. Net proceeds from the offering, after deducting underwriting discounts, commissions and offering expenses, were approximately $16.0 million.
First Quarter 2026 Financial Results
Research and Development (R&D) Expenses: R&D expenses for the three months ended March 31, 2026 decreased to $14.1 million from $16.1 million for the same period in 2025. The decrease was primarily the result of lower employee and consultant compensation, including stock-based compensation, lower engineering outside services related to our device development, and lower expensed inventory, among other variances. General and Administrative (G&A) Expenses: G&A expenses decreased to $7.9 million for the three months ended March 31, 2026 from $9.0 million for the same period in 2025. Total Operating Expenses: Total operating expenses decreased to $21.9 million for the three months ended March 31, 2026 from $25.1 million for the same period in 2025. Net Loss: INOVIO's net loss for the three months ended March 31, 2026 was $19.7 million, or $0.28 per basic and diluted share, compared to a net loss of $19.7 million, or $0.51 per basic and diluted share, for the three months ended March 31, 2025. Cash, Cash Equivalents and Short-term Investments: As of March 31, 2026, cash, cash equivalents and short-term investments were $37.7 million (excluding net proceeds from the April 2026 offering of $16.0 million), compared to $58.5 million as of December 31, 2025. Cash Guidance
INOVIO estimates that current cash, cash equivalents and short-term investments balances will support operations into the first quarter of 2027, beyond the target PDUFA date for INO-3107. This projection includes the net proceeds of $16.0 million from the public offering in April 2026, as well as an operational net cash burn estimate of approximately $18 million for the second quarter of 2026. These cash runway projections do not include any further capital-raising activities that INOVIO may undertake.
Conference Call / Webcast Information
INOVIO's management will host a live conference call and webcast with slides at 4:30 p.m. ET today to discuss INOVIO's financial results and provide a general business update. The live webcast and replay may be accessed by visiting INOVIO's website at http://ir.inovio.com/events-and-presentations/default.aspx.
About INOVIO's DNA Medicines Platform
INOVIO's DNA medicines platform has two innovative components: precisely designed DNA plasmids, delivered by INOVIO's proprietary investigational medical device, CELLECTRA. INOVIO uses proprietary technology to design its DNA plasmids, which are small circular DNA molecules that work like software the body's cells can download to produce specific proteins to target and fight disease. INOVIO's proprietary CELLECTRA delivery devices are designed to optimally deliver its DNA medicines to the body's cells without requiring chemical adjuvants or lipid nanoparticles and without the risk of the anti-vector response historically seen with viral vector platforms.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing innovative DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Forward-Looking Statements
This press release contains certain forward-looking statements relating to our business, including the timing and success of preclinical studies and clinical trials; the ability to obtain and maintain regulatory approval of our product candidates; the FDA's acceptance of our BLA for INO-3107 with a PDUFA target action date set for October 30, 2026; a yet-to-be scheduled meeting with the FDA to discuss eligibility for the accelerated approval program; the potential benefits of INO-3107 and our other potential product candidates, including our belief that INO-3107 has a positively differentiated product profile and the potential to become the preferred product by patients and their physicians, if approved; the clinical collaboration and supply agreement with Akeso Inc. to evaluate INO-5412 in combination with cadonilimab for the potential treatment of GBM in the INSIGhT trial; the scope, progress and expansion of developing and commercializing our product candidates, including the anticipated commercial launch of INO-3107, if approved; our anticipated growth strategies; our ability to establish and maintain development partnerships; our estimated operational net cash burn of approximately $18 million for the second quarter of 2026; and the expected sufficiency of our cash resources into the first quarter of 2027. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials, product development programs and commercialization activities and outcomes, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured, or commercialized, that the results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law.
Inovio Pharmaceuticals remains a high-risk, event-driven play, with the investment case dominated by the binary FDA decision for INO-3107 in October. Cost discipline has improved, with operating expenses down to $21.9M and cash projected to fund operations into 1Q27, reducing near-term dilution risk. INO-3107 offers a differentiated, patient-friendly profile versus PAPZIMEOS, targeting a potentially larger-than-expected RRP population and non-responders.
Palantir Bulls Face a Reality Check Before EarningsInovio Pharmaceuticals NASDAQ: INO shareholders approved all proposals presented at the company’s 2026 annual meeting, including the election of eight directors and the ratification of Ernst & Young LLP as the company’s independent registered public accounting firm for the year ending Dec. 31, 2026.
Simon X. Benito, chairman of Inovio’s board of directors, presided over the virtual meeting. Rob Crotty, Inovio’s general counsel, corporate secretary and chief compliance officer, said a quorum was present based on a preliminary count of shares represented by proxy.
Get Inovio Pharmaceuticals alerts:
Let the Good Times Roll: 2 Stocks Showing No Signs of SlowingThe board nominees elected were Simon Benito, Roger D. Dansey, Ann C. Miller, Jacqueline Shea, Jay Shepard, David B. Weiner, Wendy Yarno and Lota Zoth. Shareholders also approved, on a non-binding advisory basis, the compensation of Inovio’s named executive officers, and approved an amendment and restatement of the company’s amended and restated 2023 Omnibus Incentive Plan.
Crotty said the company expects to report preliminary voting results, or final results if available, in a Form 8-K filing with the Securities and Exchange Commission within four days after the meeting.
Inovio Highlights INO-3107 Regulatory Progress 3 AI Stocks in Correction Mode: Can They Rebound?Following the formal portion of the meeting, Dr. Jackie Shea, Inovio’s chief executive officer, provided an update on the company’s progress and priorities. Shea said Inovio’s work in 2025 culminated with the U.S. Food and Drug Administration’s acceptance of its first Biologics License Application for INO-3107 under the Accelerated Approval Program.
INO-3107 is Inovio’s lead DNA immunotherapy candidate in development for the treatment of recurrent respiratory papillomatosis, or RRP. Shea said the target Prescription Drug User Fee Act date for the application is Oct. 30, 2026, and that the company is focused on the potential approval and commercial launch of what would be Inovio’s first product.
Shea said the FDA has completed its standard mid-cycle review of the BLA, with “no new significant issues being raised,” and has scheduled the late-cycle review for the third quarter. She also said the FDA reiterated its intent to schedule an informal meeting to discuss a potential review issue raised in the file acceptance letter related to INO-3107’s eligibility under the Accelerated Approval pathway.
“We have indicated to the agency that we are eager to discuss this with them as we believe that 3107 meets the requirements for Accelerated Approval eligibility,” Shea said.
Company Cites Unmet Need in RRP Shea described RRP as a rare HPV-related disease estimated to affect approximately 14,000 people in the U.S. based on available epidemiological data. The disease is characterized by persistent wart-like growths called papilloma that primarily grow on the vocal cords and in the respiratory tract.
Shea said surgery remains the standard of care and that patients can undergo numerous surgeries to manage the disease. She said there is now an improved immunotherapy on the market, but added that it “doesn’t work for every patient” and includes additional surgery as part of its dosing protocol.
According to Shea, Inovio designed INO-3107 with the goal of reducing surgeries. She said the company believes the candidate could become a preferred treatment option for RRP based on efficacy and tolerability results observed to date, as well as a patient-focused treatment regimen that does not require surgery during the dosing window.
Shea said Inovio completed a Phase 1/2 open-label trial of INO-3107 in patients who required at least two surgeries in the previous year, along with a retrospective trial to assess longer-term treatment effects. She said the trials showed a statistically significant reduction in surgeries in the first 12 months following treatment, with clinical benefit continuing into the second year. She added that half of patients required no surgery in year two.
Shea said Inovio believes INO-3107 meets FDA criteria for Accelerated Approval based on its potential to provide meaningful therapeutic benefit over existing treatments and address remaining unmet need among patients.
Pipeline Partnerships and Research Updates While Inovio is directing most of its resources toward INO-3107, Shea said the company is continuing to advance other pipeline candidates through partnerships.
She highlighted a collaboration announced in February with Akeso to evaluate Inovio’s immuno-oncology candidate INO-5401 in combination with Akeso’s dual checkpoint inhibitor as a potential treatment for glioblastoma. Shea said the study will be part of a Phase 2 adaptive platform trial sponsored by the Dana-Farber Cancer Institute.
Shea also discussed Inovio’s work with The Wistar Institute, AstraZeneca and clinical investigators at the Perelman School of Medicine at the University of Pennsylvania to advance DNA-encoded monoclonal antibody technology. She said a Phase 1 proof-of-concept trial published in Nature Medicine in October demonstrated the technology’s ability to produce monoclonal antibodies within the human body.
Shea said Inovio’s DNA-encoded protein technology builds on that research and is aimed at enabling additional types of proteins to be made within the body to treat diseases caused by missing or defective proteins. She noted that Inovio has presented preclinical work on factor VIII production for hemophilia A and is seeking partnerships for rare disease targets including Fabry disease and hypophosphatasia.
Financial Position Shea said financial discipline remains central to Inovio’s strategy as it focuses resources on advancing INO-3107. She said the company reduced total operating spend for 2025 by 23% compared with 2024, and that operating expenses declined 13% in the first quarter of 2026 compared with the first quarter of 2025.
Inovio ended the first quarter of 2026 with $37.7 million in cash, cash equivalents and short-term investments. Shea said the company also completed a public equity offering in April 2026 that provided net proceeds of approximately $16 million. Based on current operating plans, she said Inovio estimates its cash runway extends into the first quarter of 2027.
Shea concluded by saying the company is focused on upcoming milestones, including the potential approval and launch of INO-3107 and the opportunity to introduce what she described as the first DNA medicine in the United States.
About Inovio Pharmaceuticals NASDAQ: INOInovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio's business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.
Central to Inovio's platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Inovio Pharmaceuticals Right Now?Before you consider Inovio Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inovio Pharmaceuticals wasn't on the list.
While Inovio Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
, /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following scientific and investor conferences:
Jefferies Global Healthcare Conference (New York)
Date: Thursday, June 4
Time: 8:45 AM ET
Format: Fireside Chat
Webcast: https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/adRiTkvKf4AnDsZYyXatz8
World Orphan Drug Congress (Boston)
Poster Presentation: Rare Disease Protein Replacement Therapeutics: The Transformational Potential of Next-Gen DNA Medicine Date: Thursday, June 11
Time: 12:00 – 12:10 PM ET
A replay of the investor event will be available for 90 days at the link above. Members of INOVIO's management team will also be conducting one-on-one meetings with investors during the investor conference.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
New York, New York--(Newsfile Corp. - June 1, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) breached their fiduciary duties to shareholders.
According to a federal securities lawsuit, Insiders at Inovio Pharmaceuticals caused the company to misrepresent or fail to disclose that (i) manufacturing for Inovio's CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's overall regulatory and commercial prospects were overstated.
If you currently own INO and purchased prior to October 10, 2023 please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Why Your Participation Matters:
As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) breached their fiduciary duties to shareholders.
According to a federal securities lawsuit, Insiders at Inovio Pharmaceuticals caused the company to misrepresent or fail to disclose that (i) manufacturing for Inovio’s CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA’s eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107’s overall regulatory and commercial prospects were overstated.
If you currently own INO and purchased prior to October 10, 2023 please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Why Your Participation Matters:
As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™
, /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) breached their fiduciary duties to shareholders.
According to a federal securities lawsuit, Insiders at Inovio Pharmaceuticals caused the company to misrepresent or fail to disclose that (i) manufacturing for Inovio's CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's overall regulatory and commercial prospects were overstated.
If you currently own INO and purchased prior to October 10, 2023 please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
Why Your Participation Matters:
As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™
